Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 10 (4), 581-6

Risk of Clostridium Difficile Infection With the Use of a Proton Pump Inhibitor for Stress Ulcer Prophylaxis in Critically Ill Patients

Affiliations

Risk of Clostridium Difficile Infection With the Use of a Proton Pump Inhibitor for Stress Ulcer Prophylaxis in Critically Ill Patients

Youngouk Ro et al. Gut Liver.

Abstract

Background/aims: Proton pump inhibitors (PPIs) and histamine-2 receptor antagonists (H2RAs) are commonly prescribed for stress ulcer prophylaxis (SUP) in critically ill patients. Several studies have suggested that the use of PPIs is a potential risk factor for Clostridium difficile infection (CDI). We compared the incidences of CDI in the PPI group and H2RA group for SUP in critically ill patients.

Methods: From August 2005 to July 2012, the incidences of CDI were retrospectively analyzed in patients who were admitted directly to intensive care units and stayed for more than 3 days. SUP-related CDI was defined as a CDI diagnosed during the SUP period. Patient clinical data were analyzed to identify potential risk factors for SUP-related CDI.

Results: Of the 1,005 patients enrolled (444 patients received PPI and 561 received H2RA), 38 (3.8%) were diagnosed with SUP-related CDI. The incidence of SUP-related CDI was considerably higher in patients who received PPI than in those who received H2RA (6.7% vs 1.8%). PPI use for SUP (odds ratio [OR], 3.3; confidence interval [CI], 1.5 to 7.1; p=0.003) and diabetes mellitus (OR, 2.3; CI, 1.2 to 4.7; p=0.019) were independent risk factors for SUP-related CDI.

Conclusions: PPI therapy is associated with a higher risk of SUP-related CDI than H2RA therapy in critically ill patients.

Keywords: Clostridium difficile; Critical care; Histamine-2 receptor antagonist; Proton pump inhibitor.

Figures

Fig. 1
Fig. 1
Flow diagram of the study. ICU, intensive care units; PPI, proton pump inhibitor; H2RA, histamine-2 receptor antagonists; CDI, Clostridium difficile infection.

Similar articles

See all similar articles

Cited by 11 PubMed Central articles

See all "Cited by" articles

References

    1. Kenneally C, Rosini JM, Skrupky LP, et al. Analysis of 30-day mortality for clostridium difficile-associated disease in the ICU setting. Chest. 2007;132:418–424. doi: 10.1378/chest.07-0202. - DOI - PubMed
    1. Doh YS, Kim YS, Jung HJ, et al. Long-term clinical outcome of Clostridium difficile infection in hospitalized patients: a single center study. Intest Res. 2014;12:299–305. doi: 10.5217/ir.2014.12.4.299. - DOI - PMC - PubMed
    1. Sesler JM. Stress-related mucosal disease in the intensive care unit: an update on prophylaxis. AACN Adv Crit Care. 2007;18:119–126. - PubMed
    1. Quenot JP, Mentec H, Feihl F, et al. Bedside adherence to clinical practice guidelines in the intensive care unit: the TECLA study. Intensive Care Med. 2008;34:1393–1400. doi: 10.1007/s00134-008-1059-y. - DOI - PubMed
    1. Cook DJ, Fuller HD, Guyatt GH, et al. Risk factors for gastrointestinal bleeding in critically ill patients: Canadian Critical Care Trials Group. N Engl J Med. 1994;330:377–381. doi: 10.1056/NEJM199402103300601. - DOI - PubMed

Substances

Feedback